Novo Nordisk (NOVOB DC) takes legal action against Hims & Hers (HIMS) to protect patients from unsafe, knock-off Wegovy and Ozempic
Newsquawk Staff ·
- Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages
What it means
Novo Nordisk's legal action against Hims & Hers is significant as it aims to protect its patented products, Wegovy and Ozempic, from what it claims are unsafe knock-offs. This move could have implications for Hims' market position and potentially impact consumer confidence in their offerings, while reinforcing Novo Nordisk's intellectual property rights and market exclusivity.
Sources
- HP (HPQ), Asus (2357 TT) and Acer (2353 TT) are shifting some PC production from Thailand and Vietnam back to China to combat soaring component costs driven by AI-related memory and storage shortages, reports Nikkei citing sources
- Universal Music Group (UMG NA) discusses going private with buyout firms, according to Bloomberg
- Japan's Sakana AI to build homegrown model to cut US and China reliance, reports Nikkei
- Japan's Sakana AI to build homegrown model to cut US and China reliance, Nikkei reports
- Novo Nordisk (NOVOB DC) says investigational cagrisema 2.4 mg/2.4 mg showed 25% average weight loss in women in redefine 1 post hoc analysis
Related headlines
- Foxconn (2317 TT) has brought online an AI factory powered by an NVIDIA (NVDA) DGX supercomputing cluster1 day ago
- US FDA has approved Novo's (NOVOB DC) once-weekly insulin treatment for paediatric patients with type 2 diabetes mellitus4 days ago
- Meta's (META) Muse AI to counter China models with subscribers, not ads, Nikkei reports4 days ago
- Toyota (TM) to recall 68k late model 2022-2024 Lexus NX vehicles in the US due to a display flaw4 days ago
- Genmab (GMAB) Phase 3 Rina data in ovarian cancer shows PFS and OS endpoints were met4 days ago
- TikTok’s US entity is reportedly exploring deals to secure multiple gigawatts of computing capacity over the coming years, according to CNBC4 days ago
- Infosys (INFY) Q2 2026 (INR): Net profit 78.2bln (exp. 79.3bln ), revenue 492.4bln (exp. 491.3bln); lowers FY27 revenue view4 days ago
- Anthropic and Hg have agreed to form an independent consultancy Co. targeting corporate clients, FT reports citing sources4 days ago
- European Commission will discuss drug pricing concerns raised by EU countries and pharmaceutical companies as they navigate US pressures, reports Politico5 days ago
- DeepSeek and Minimax get license for overseas use, reports Chinese Media5 days ago
- Infineum is exploring a USD 8bln sale, the FT reports5 days ago
- Schneider Electric (SU FP) announces a strategic collaboration with Nvidia (NVDA) and HPE (HPE) to accelerate the adoption of Physical AI across process and heavy industries5 days ago
- Evonik (EVK GY) is considering acquiring Ashland (ASH), Handelsblatt reports citing sources5 days ago
- BioNTech (BNTX / 22UA GY) has advanced a Phase 3 trial of pumitamig with Gliead (GILD)5 days ago
- LG Innotek (011070 KS) is to build sensing solutions with Nvidia (NVDA)5 days ago